COVID Vaccine, Influenza, & RSV Resource Page
Updated: 9/19/23
These resources will be updated as the respiratory viral season and product availability change in Chicago and across the United States.
Reach out to adsp@nm.org for questions regarding this content.
These resources will be updated as the respiratory viral season and product availability change in Chicago and across the United States.
Reach out to adsp@nm.org for questions regarding this content.
COVID-19, Influenza, and RSV Vaccine Frequently Asked Questions:
Co-administration of Vaccines:
Live flu vaccine considerations:
For patient facing information: See FDA Resources for Fall Respiratory Illness Season |
Which vaccines and products are available:
For vaccine locations: see the CDC vaccines.gov |
Viral Vaccine Specific FAQ Continued:
COVID-19 vACCINES
See CDC COVID Vaccine FAQ for further patient FAQs.
Disclaimer: resource links are updated frequently
Disclaimer: resource links are updated frequently
COVID-19 Vaccine Schedules Adult and Children ≥12 years old:
Special populations and FAQ:
|
COVID-19 Vaccine Schedules for Children <12 years old:
|
Influenza vACCINES
For comprehensive information, see CDC Flu Vaccine Site.
Vaccine products available at NM:
Special population FAQ:
Influenza vaccination after antivirals: inactivated vaccines are appropriate anytime.
Vaccine products available at NM:
- Regional Medical Group/Northwestern Medical Group: Fluzone (0.5 mL IM; ≥ 6 months old) and High-dose Fluzone (0.7 mL IM; ≥65 years old)
- Regional Medical Group, Northwestern Workforce, Non-Ambulatory: Fluarix (0.5 mL IM; ≥ 6 months old)
- Available at all sites: Flublok (0.5 mL IM; ≥18 years old) and Flumist (0.2 mL intranasal 2 to 49 years old)
Special population FAQ:
- Pregnancy/Chronic Medical Conditions/Immunocompromised: Avoid Flumist intranasal (live vaccine)
- 6 months – 8 years: should receive two doses of the influenza vaccine for their first season
- Age 65+: high dose vaccine is recommended
- Caregivers/Contacts of High risk patients who receive Flumist intranasal (live vaccine) should avoid severely immunocompromised patient for 7 days
- Egg allergy: can receive any flu vaccine formulation
- If previous severe allergic reaction to flu vaccine, avoid formulations that contain eggs
- In patients recovering from moderate to severe infection related illness, no flu vaccine wait period beyond illness recovery
- Reimbursement / patient cost:
- Medicare Part B: covered with no patient cost-sharing
- Medicaid/CHIP: covered with no patient cost-sharing
Influenza vaccination after antivirals: inactivated vaccines are appropriate anytime.
- Avoid giving Live attenuated vaccine (Flumist intranasal vaccine) after the patient received:
- Oseltamivir/Zanamivir: 48 hours before or 2 weeks after
- Peramivir: 5 days before or 2 weeks after
- Baloxavir: 17 days before or 2 weeks after
RSV VACCINE AND PEDIATRIC MONOCLONAL ANTIBODY
RSV Vaccines for ≥60 years old:
RSV Pediatric mAB Product (nirsevimab):
- Expected to be available at NM prior to RSV season in October: Abrysvo (Pfizer) 0.5 mL IM x1 dose
- Any patient ≥60 years old may receive an RSV vaccine with shared clinical decision making
- Risk factors for severe disease include: Chronic medical conditions (cardiopulmonary disease, kidney disorders, liver disorders, neurologic or neuromuscular conditions, hematologic disorders, diabetes, moderate to severe immunocompromise), frailty, advanced age, nursing home/long-term care facility residents
- Reimbursement / patient cost:
- Medicare Part D: covered with no patient cost-sharing
- Patients must have Part D for coverage. The patient may have to pay a vaccine administration fee at the time of service, but they can get reimbursed in full for this fee from their Part D plan
- Medicaid/CHIP: covered with no patient cost-sharing
- Medicare Part D: covered with no patient cost-sharing
- FDA approved in pregnancy during 32-26 weeks gestational age for the prevention of severe infant RSV infection. RSV vaccine use recommendations for pregnant patients are expected from the CDC fall of 2023.
- Expected to be available at NM prior to RSV season in October: Abrysvo (Pfizer) 0.5 mL IM x1 dose
RSV Pediatric mAB Product (nirsevimab):
- Expected to be available to NM patients in October
- Recommended by the CDC to be given to newborns within 1 week of birth (during RSV season)
- Also recommended for children 8-19 months old who are at increased risk of severe RSV disease entering their second RSV season
- Pediatric RSV mAB (nirsevimab) + routine childhood vaccines: ok to give simultaneously
- Use in infants whose mother received the RSV vaccine: the CDC is expected to provide clarity in the fall of 2023
- See AAP FAQ resource for more nirsevimab information
- See ACIP and AAP resource for additional information for patients post palivizumab (Synagis)
- For patients who received cardiopulmonary bypass, see Beyfortus package insert for dosing
- < 5 kg: 50 mg IM x1 dose
- ≥ 5 kg: 100 mg IM x1 dose
- 200 mg x1 dose (2x 100 mg IM doses at once)
Treatment and Post-Exposure Prophylaxis (PEP):
COVID-19
See the COVID-19 webpage for treatment
Influenza
Oseltamivir
Treatment:
|
Baloxavir
Treatment and prophylaxis (regimen are the same):
|
Influenza post-exposure prophylaxis (PEP) considerations:
- Indications for PEP with oseltamivir:
- Patients receiving PEP should be educated to seek medical evaluation if they develop a febrile respiratory illness
- For hospitalized and LTC outbreak settings, oseltamivir should be given for at least two weeks and continuing up to one week after last known case
RSV
No routine antiviral treatment for RSV is recommended at this time.